# BioLynx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biolynx

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.biolynx.cn
- Latest round: Series A (Mar 26, 2021)
- Investors on record: 6

## About

Established in 2015 and based in Hangzhou, China, Hangzhou Bailing Biotechnology Co., Ltd., trading as BioLynx, operates as a biotechnology company that focuses on developing in vitro diagnostic reagents and antibody. In 2016, the company established a scientific antibody research and development and production base. In 2020, it acquired EU CE certification. In March 2026, BioLynx closed a venture funding.

The company's main products include LYNX310 equipment, immunochromogenic systems and auxiliary reagents, and RUO reagents. The LYNX310 device provides full-process services from baking to counterstaining in immunohistochemistry experiments.

The company’s revenue is generated by providing antibody screening solutions.

## Funding rounds

- Series A, Mar 26, 2021 — CAS Investment Management, GoldHold Wisdom Venture Capital
- Series A, Apr 10, 2018 — Puhua Capital
- Angel, Dec 1, 2015 — Share Capital, Bio4p, GoldHold Wisdom Venture Capital, Huaanpuchu

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Angel
- Bio4p — Angel
- GoldHold Wisdom Venture Capital (https://capitalatlas.ai/funds/goldhold-wisdom-venture-capital) — Angel, Series A
- Huaanpuchu — Angel
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A